earningsconfidence high
Ceribell Q1 revenue $26.5M (+29% YoY); raises FY2026 guidance to $112-116M
Ceribell, Inc.
2026-Q1 EPS
reported -$0.52
vs consensus -$0.40
▼ miss
(-30.7%)
- Revenue $26.5M, up 29% YoY; product $20.2M, subscription $6.3M, both +29%.
- Net loss $19.7M ($0.52/sh) vs $12.8M ($0.36) YoY; adj. EBITDA loss $11.2M.
- Launched neonate/pediatric EEG products; 680 active accounts at quarter end.
- CMS proposed rule for NTAP reimbursement for delirium monitoring; final rule Aug 2026.
- FY2026 revenue guidance raised to $112-116M (26-30% growth); cash $141.2M.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.